Facebook
Twitter
LinkedIn
Forward
2020 Macula Society 43rd Annual Meeting
Founded in 1977, the Macula Society is a forum for new research in retinal vascular and macular diseases. Membership is by application, with acceptance criteria including extensive contribution to retinal literature. The Macula Society recognizes outstanding achievement by its members and others through awards and lectures, and holds an annual meeting open to members, their guests co-authors, and supporting company representatives.
The annual meeting of the Macula Society is a platform of clinicians, clinical researchers, and translational scientist from around the world to gather, present, discuss, and integrate new data and new ideas relevant to the clinical care of patients with diseases of the retina and vitreous.
This activity is being supported by an unrestricted educational grant from: Clearside, Optos, and Heidelberg Engineering
Target Audience
Ophthalmologist
Learning Objectives
At the end of this activity, I will be able to:
- Demonstrate primary results of clinical trial results
- Evaluate the strengths and weaknesses of evidence for new and novel treatment of retinal disease
- Integrate information from multiple sources to inform treatment decisions and establish best practices for treatment of patients
All persons in control of content have NO relevant relationships to disclose with the exception of:
| Name | Company | Role |
| Michael Ip, MD | Boehringer Ingelheim, Thrombogenics, Quark, Omeros, Allergan, Amgen, Astellas, Alimera, Novartis, Genentech, Clearside, Biogen | Consultant, Research |
| Caroline Baumal, MD | Novartis, Genentech, Zeiss | Speaker |
| Pravin Dugel, MD | Graybug Vision | Consultant |
| Joan Miller, MD | Sunovion, KalVista Pharmaceuticals, ONL Therapeutics, Mass. Eye and Ear/Valeant Pharmaceuticals, Lowy Medical Research Institute | Consultant, Royalties, Grant Support |
| David Sarraf, MD | Amgen, Bayer, Genentech, Novartis, Optovue, Heidelberg, Regeneron | Consultant, Speaker |
Click here for the full list of Planner and Speaker Financial Disclosures
In accordance with the ACCME® standards for Commercial Support # 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of resolution process and resolved.
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and The Macula Society. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Live activity for a maximum of 18.50 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 18.50 hours of participation for continuing education for allied health professionals.
Available Credit
- 18.50 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 18.50 Hours of ParticipationHours of Participation credit.